GEN News Highlights

A plurality of those who took a recent GEN poll isn’t sure what to make of President Barack Obama’s proposed FDA and CDC budgets for the 2013 fiscal year. When asked how helpful they thought Obama’s proposed budget would be for both agencies, 42.9% were “undecided,” another 28.6% replied “not much,” while even percentages (14.3% each) took a more optimistic view, saying the FY 2013 budget would be “very” or “somewhat” helpful.

Under the president’s budget, FDA would see its budgetary authority inch up by 0.4% to $2.517 billion. When industry user fees are included, however, FDA’s total program spending would jump 17% to $4.486 billion. CDC would see its discretionary budget authority shrink by 11.6%, or $664 million, to $5.068 billion. After nondiscretionary spending is factored in, total CDC funding rises by 0.4% to $11.236 billion in FY ’13.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.1%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.